| Regen BioPharma Inc (RGBP) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Q1-CY2026 | Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 | Q1-CY2014 | |
| Balance Sheet Date | 2025-Sep-30 | 2025-Jun-30 | 2025-Mar-31 | 2024-Dec-31 | 2024-Sep-30 | 2024-Jun-30 | 2024-Mar-31 | 2021-Mar-31 | 2020-Dec-31 | 2020-Sep-30 | 2020-Jun-30 | 2020-Mar-31 | 2019-Dec-31 | 2019-Sep-30 | 2019-Jun-30 | 2019-Mar-31 | 2018-Dec-31 | 2018-Sep-30 | 2018-Jun-30 | 2018-Mar-31 | 2017-Dec-31 | 2017-Sep-30 | 2017-Jun-30 | 2017-Mar-31 | 2016-Dec-31 | 2016-Sep-30 | 2016-Jun-30 | 2016-Mar-31 | 2015-Dec-31 | 2015-Sep-30 | 2015-Jun-30 | 2015-Mar-31 | 2014-Dec-31 | 2014-Sep-30 | 2014-Jun-30 | 2013-Sep-30 | |||||||||||||
| Fiscal Period | Q4-FY2025 | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | Q3-FY2024 | Q2-FY2024 | Q2-FY2021 | Q1-FY2021 | Q4-FY2020 | Q3-FY2020 | Q2-FY2020 | Q1-FY2020 | Q4-FY2019 | Q3-FY2019 | Q2-FY2019 | Q1-FY2019 | Q4-FY2018 | Q3-FY2018 | Q2-FY2018 | Q1-FY2018 | Q4-FY2017 | Q3-FY2017 | Q2-FY2017 | Q1-FY2017 | Q4-FY2016 | Q3-FY2016 | Q2-FY2016 | Q1-FY2016 | Q4-FY2015 | Q3-FY2015 | Q2-FY2015 | Q1-FY2015 | Q4-FY2014 | Q3-FY2014 | Q2-FY2014 | |||||||||||||
| Operating Cash Flow | (160,005$) | (55,977$) | (101,230$) | (66,379$) | (207,289$) | (172,589$) | (209,322$) | (162,336$) | (23,405$) | (87,008$) | 0$ | 0$ | 0$ | 0$ | (5,657$) | 24,302$ | (136,964$) | (67,291$) | (127,505$) | (150,032$) | (465,636$) | (81,429$) | (403,506$) | (627,265$) | (623,017$) | (417,208$) | (349,899$) | (504,295$) | (398,495$) | (410,854$) | 973,543$ | (425,403$) | (338,962$) | (388,392$) | (268,190$) | (197,103$) | |||||||||||||
| Investing Cash Flow | 0$ | 0$ | 0$ | 0$ | 0$ | 0$ | 0$ | 0$ | 49,858$ | 0$ | (5,741$) | 0$ | 0$ | ||||||||||||||||||||||||||||||||||||
| Purchases of Property and Equipment | |||||||||||||||||||||||||||||||||||||||||||||||||
| Financing Cash Flow | 227,799$ | 55,976$ | 102,856$ | 65,799$ | 146,157$ | 156,324$ | 165,797$ | 143,750$ | 0$ | 0$ | 0$ | 0$ | 0$ | 5,300$ | (31,800$) | 143,008$ | 54,013$ | 103,500$ | 131,250$ | 418,250$ | 111,500$ | 172,872$ | 619,000$ | 491,363$ | 2,590,738$ | 242,340$ | 700,191$ | 283,000$ | 445,147$ | (1,036,036$) | 555,300$ | 169,000$ | 75,001$ | 736,542$ | 250,725$ | 140,969$ | 95,000$ | ||||||||||||
| End Cash Position | 69,555$ | 135$ | 716$ | 61,849$ | 78,114$ | 121,037$ | 692$ | 87,700$ | 51,204$ | 0$ | 0$ | 0$ | 0$ | 0$ | 357$ | 7,855$ | 1,812$ | 15,090$ | 39,095$ | 8,019$ | 55,404$ | 31,074$ | 261,708$ | 269,973$ | 401,627$ | 113,159$ | 24,822$ | 106,024$ | 168,517$ | 38,620$ | 521,974$ | 53,622$ | 0$ | 49,395$ | |||||||||||||||
| Exchange Rate Effect | |||||||||||||||||||||||||||||||||||||||||||||||||
| Dividends Paid | |||||||||||||||||||||||||||||||||||||||||||||||||
| Unlevered Free Cash Flow | (160,005$) | (55,977$) | (101,230$) | (66,379$) | (207,289$) | (172,589$) | (209,322$) | (162,336$) | (23,405$) | (87,008$) | 0$ | 0$ | 0$ | 0$ | (5,657$) | 24,302$ | (136,964$) | (67,291$) | (127,505$) | (150,032$) | (465,636$) | (81,429$) | (403,506$) | (627,265$) | (623,017$) | (417,208$) | (349,899$) | (504,295$) | (398,495$) | (410,854$) | 973,543$ | (425,403$) | (338,962$) | (388,392$) | (268,190$) | (197,103$) | |||||||||||||